Meeting Coverage

Meeting Coverage

Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma

Irene Ghobrial, MD, shares results from a phase II trial, in which 84 percent of patients with high-risk smoldering multiple myeloma responded to treatment...

PERIOP 2: Do Patients at High Risk for Arterial Thromboembolism Need LMWH Bridging?

Michael Kovacs, MD, discusses results from the PERIOP 2 trial, which found that post-procedure bridging with low-molecular weight heparin during warfarin interruption offered no...

A New Personalized Risk-Stratification Model for Myelodysplastic Syndromes

Dr. Nazha discusses a new tool for the risk-stratification of patients with myelodysplastic syndromes, which outperformed traditional risk models.

Evaluating a Venetoclax and Carfilzomib Combination in Myeloma

Luciano Costa, MD, PhD, shares findings from a phase II study, in which the combination appeared tolerable and effective in patients with relapsed/refractory myeloma.

Is Luspatercept a New Option for Patients With MDS?

Dr. List discusses results from the MEDALIST trial in patients with transfusion-dependent myelodysplastic syndromes, which were presented as a plenary abstract at the 2018...

Ibrutinib Outperforms Chemoimmunotherapy in CLL

Dr. Woyach shares findings from her plenary abstract, in which ibrutinib improved survival outcomes in older patients with chronic lymphocytic leukemia, compared with a...

Four or Six Cycles of CHOP in Younger DLBCL Patients?

Viola Poeschel, MD, discusses results from the Flyer trial, which showed that younger, fit patients with diffuse large B-cell lymphoma can be treated with...

AMG 330 Takes a BiTE out of Relapsed/Refractory AML

Farhad Ravandi-Kashani, MD, discusses results from the first-in-human trial showing the bispecific T-cell engager antibody was tolerable in patients with previously treated acute myeloid leukemia.
video

Expanding Acalabrutinib to Waldenström Macroglobulinemia

Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
video

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.